[News Focus] Why Kim Jong-un spotlights mothers
‘Korea could go extinct without proper immigration policy’: minister
LG Display launches voluntary redundancy program in efficiency drive
S. Korea, US, Japan to discuss regional security issues: White House
[KH Explains] Banks, regulators trade blame for snowballing ELS losses
Samsung Biologics inks $81m deal with NovartisBy Kan Hyeong-woo
Published : June 7, 2022 - 15:53
According to the contract manufacturing giant’s regulatory filing, the two sides on Friday signed the initial contract, which is equivalent to 6.41 percent of the company’s annual sales of 1.57 trillion won ($1.25 billion) last year. It did not reveal which of Novartis’ biopharmaceutical products Samsung Biologics will manufacture.
Samsung Biologics said the intent signing has binding powers between the two firms and it will disclose the confirmed details after they sign the main contract in the future.
The signing marked the first time for Samsung Biologics to secure a deal from Novartis.
“The letter of intent was the first contract between the two firms. We look forward to continue to have cooperative relations through this deal in the future,” said a Samsung Biologics official.
Novartis is the fifth-largest pharmaceutical company in the world with annual revenue of $51.6 billion last year, according to PharmaBoardroom.
S. Korea eyes chip alliance with Netherlands
SK carries out complete reshuffle of top brass
Suneung without 'killer questions' still not easy, results show